Jump to content
Invision Community
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
META-99 SEARCH ENGINE             CONTACT US

Stella Wilson

Members
  • Content Count

    64
  • Joined

  • Last visited

Everything posted by Stella Wilson

  1. Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The USD 2.7 billion and USD 600 million (by 2030) financial opportunity within the large volume wearable injectors market for the delivery of insulin and of non-insulin drugs, respectively, has been analyzed across the following segments: Key Inclusions · An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device / personal diabetes manager (PDM) / smartphone) in the insulin delivery devices. · A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems (in case of insulin devices). · Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products. · An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant types of deals. · A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2000, and offering a means for other industry stakeholders to identify potential acquisition targets. · An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors over the last three decades. It also highlights the key parameters associated with the patents, including information on patent type, issuing authority / patent offices involved, Cooperative Patent Classification (CPC) symbols, emerging areas (in terms of number of patents filed / granted), company type and leading industry, non-industry and individual patent assignees (in terms of size of intellectual property portfolio). · A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, identified on the basis of an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). · A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter. The analysis was based on tweets posted on the platform in the last few years. · A detailed analysis of completed, ongoing and planned clinical trials of various large volume wearable injector products based on the various relevant parameters, such as trial registration year, current trial phase, trial status, study design, study focus, targeted therapeutic area and clinical outcomes. · A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. It includes information on the services provided by contract service providers for manufacturing of various device components (primary containers), infusion sets, adhesives, closures and injection moldings. · An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe. · Informed estimates of the existing market size and the future opportunity for large volume wearable injectors, over the next decade. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an estimate on the likely evolution of the large volume wearable injectors market, for the delivery of both insulin and non-insulin drugs, over the period 2020-2030. The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Type of Device · Patch Pump / Injectors · Infusion Pump / Injectors Product Usability · Disposable · Re-usable Therapeutic Area (for non-insulin drugs) · Neurological Disorders · Cardiovascular Disorders · Oncological Disorders · Infectious Disorders Key geographical regions · North America · Europe · Asia Pacific The report features inputs from eminent industry stakeholders, according to whom, large volume injectors are generally preferred for the delivery of biologics, which cannot be easily administered orally. The report includes detailed transcripts of discussions held with the following experts: · Mark Banister (CEO, Medipacs) · Michael Hooven (CEO, Enable Injections) · Jesper Roested (CEO, Subcuject) · Pieter Muntendam (Former President and CEO, scPharmaceuticals) · Menachem Zucker (Vice President and Chief Scientist, Elcam Medical) · Graham Reynolds (Vice President and General Manager, Biologics, West Pharmaceutical Services) · Mindy Katz (Director of Product, Sorrel Medical) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  2. The “Global Handheld Ultrasound Imaging Devices Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Key Inclusions · An overview of the current market landscape of the handheld ultrasound imaging devices, providing information on the status of development, application area (abdomen, cardiac, gynecological, pulmonary, urological scanning and others), weight of device, type of transducer array (convex / curved, linear, micro-convex, transvaginal, phased and others), transducer frequency, mode of imaging (brightness, color doppler, motion, power doppler, pulsed wave, tissue harmonic and others), field of view, scanning depth, type of software (smartphone application and customized software application), connectivity provision (universal serial bus (USB), cellular / WiFi and bluetooth), data management feature(s) (internal, external, and cloud / remote monitoring), battery backup and cost of device. In addition, it presents details of the device developers, highlighting year of establishment, company size, type of business model used (B2B and B2C), target market (domestic and domestic and international) and location of headquarters. Further, it highlights the key initiatives taken by the various device developers to tackle the on-going global pandemic of COVID-19. · An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of handheld ultrasound imaging devices, based on the parameters, such as application area, mode of imaging, number of devices and company size, a grid representation illustrating the distribution of scanners based on application area, type of transducer array and type of software, [C] an insightful heat map representation, highlighting the distribution of devices on the basis of application area and mode of imaging, and [D] a tree map representation of the handheld ultrasound imaging devices, distributed on the basis of mode of imaging and connectivity provision. · Elaborate profiles of mid-sized / large companies that are engaged in the development of handheld ultrasound imaging scanners. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook. · A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength of product portfolio, type of software, mode of imaging, connectivity provisions, geographical presence / reach and supplier power of each company. · An analysis of the partnerships that have been inked by stakeholders in the domain, during the time period 2010-2020 (till April), covering licensing agreements, acquisitions and mergers, research and development agreements, product distribution agreements and other relevant types of deals. · An insightful analysis highlighting cost saving potential associated with the use of handheld ultrasound imaging devices, based on information from close to 50 countries, taking into consideration various parameters, such as total number of radiologists, annual salary, number of ultrasound scans performed and increase in efficiency by adoption of these handheld ultrasound imaging devices. · An informed estimate of the global demand for handheld ultrasound imaging devices for the period 2020-2030, taking into account the impact of COVID-19, historical sales of these devices, and annual revenues (generated by sales of these devices) of prominent device manufacturers. · A review of the product distribution strategies adopted by different device-developers, demand and market attractiveness for handheld ultrasound imaging devices across different types of end-users, including ambulatory surgical centers, diagnostic imaging centers, hospitals, maternity clinics, specialty clinics, and other end-users. · An insightful discussion on the impact of COVID-19 on the overall handheld ultrasound imaging devices market, along with the key lessons learnt from big pharma players in 2008 recession. · An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till April) and insights from the recent news articles related to handheld ultrasound imaging devices, indicating the increasing popularity of this domain. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Application Area · Cardiac Scanning · Emergency Medicines · Gynecological / Obstetrics Scanning · Musculoskeletal Scanning · Pulmonary Scanning · Urological Scanning · Vascular Surgery · Other Application Areas Type of Transducer Array · Curved · Endocavity · Linear · Phased · Other Scanners Type of Software · Smartphone Applications · Customized Software End-Users · Ambulatory Surgical Centers · Diagnostic Imaging Centers · Hospitals · Maternity Clinics · Specialty Clinics · Other End-Users Key Geographical Regions · North America · Europe · Asia-Pacific and the Rest of the World The report includes detailed transcripts of discussions held with the following experts: · Stefan Maas (Chief Executive Officer, SomaView) · Anais Concepcion (Director of Content and Campaign Management, EchoNous) · Zhengzheng Zhu (Oversea Business Development, PeakSonic) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  3. The “Bispecific Antibody Therapeutics Market, 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. Key Inclusions · A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. · A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above) development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain. · Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available). · Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules, [C] a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies and [D] the chapter also includes an insightful summary representation using the logos of different industry stakeholders, highlighting the distribution of companies based on the company size. · An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and target therapeutic area. · An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals. · A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO. · A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial. · A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences. · A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Therapeutic Area · Autoimmune Disorders · Eye Disorders · Genetic Disorders · Hematological Malignancies · Infectious Diseases · Inflammatory Disorders · Skin Disorders Mechanism of Action · Cytokines Retargeting / Neutralization · Dual Ligands Blocking · T-cell Retargeting / Activation · Others Target Antigens · CD3 x CD19 · CD30 x CD16A · Factor IXa x Factor X · IL-1α x IL-1β · IL-13 x IL-4 · IL-17A x Albumin · IL-17A x IL-17F · Psl x PcrV · VEGF-A x ANG2 · Others Key Players · Astra Zeneca · Amgen · AbbVie · Affirmed · Affibody · Merck · Roche · Sanofi · Taisho Pharmaceutical Key Geographical Regions · North America · Europe · Asia-Pacific The report features inputs from eminent industry stakeholders, according to whom this relatively novel class of antibody therapeutics is likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts: · Martin Steiner (Chief Executive Officer, Synimmune) · Ludger Große-Hovest (Chief Scientific Officer, Synimmune) · Jane Dancer (Chief Business Officer, F-Star) · Siobhan Pomeroy (Senior Director, Business Development, Cytom X) · Yinjue Wang (Associate Director, Process Development, Innovent Biologics) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  4. Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs. The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments: Type of Product Manufactured · Active Pharmaceutical Ingredients (APIs) · Finish Drug Formulations (FDFs) Type of Type of Formulation · Solid Formulations · Oral Liquids · Injectables · Others Scale of Operation · Clinical · Commercial Company Size · Small-sized · Mid-sized · Large Key Geographical Regions · North America · Europe · Asia-Pacific and Rest of the World The Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: · Bristol Myers Squibb · GlaxoSmithKline · Incyte · Novartis · Trillium Therapeutics Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Company Profiles 6. Regional Capability Analysis 7. Likely Partner Analysis 8. Clinical Trial Analysis 9. Capacity Analysis 10. Demand Analysis 11. Make versus Buy Decision Making Framework 12. Microbiome related initiatives of Big Pharmaceutical Players 13. Market Forecast 14. Conclusion 15. Executive Insights 16. Appendix 1: Tabulated Data 17. Appendix 2: List of Companies and Organizations 18. Appendix 3: List of Probiotic Supplement Contract Manufacturers and Microbial Contract Service Providers For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  5. The convenience of subcutaneous route of drug administration and the reformulation of intravenous drugs, reaching patent expiry, for SC delivery has provided an impetus to the development of large volume wearable injectors. In fact, according to the experts in this field, the industry is putting in significant efforts to develop efficient and effective drug-device combinations to deliver large volumes of drugs over a convenient period of time. The USD 2.7 billion and USD 600 million (by 2030) financial opportunity within the large volume wearable injectors market for the delivery of insulin and of non-insulin drugs, respectively, has been analyzed across the following segments: Type of Device · Patch Pump / Injectors · Infusion Pump / Injectors Product Usability · Disposable · Re-usable Therapeutic Area (for non-insulin drugs) · Neurological Disorders · Cardiovascular Disorders · Oncological Disorders · Infectious Disorders Key geographical regions · North America · Europe · Asia Pacific The report Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices features the following companies, which we identified to be key players in this domain: · Becton Dickinson · Bespak (subsidiary of Consort Medical) · CeQur · Debiotech · Eli Lilly · Enable Injections · Insulet · Medtronic · PharmaSens · Roche · SOOIL Development · Sonceboz · Sensile Medical (acquired by Gerresheimer) · SteadyMed Therapeutics (acquired by United Therapeutics) · Tandem Diabetes Care · Weibel CDS (acquired by SHL Medical) · West Pharmaceutical Services Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Large Volume Wearable Injectors: Current Market Landscape 5. Product Competitiveness Analysis 6. Large Volume Wearable Injectors: Key Players 7. Drug Device Combinations: Tabulated Profiles 8. Partnerships and Collaborations 9. Key Acquisition Targets 10. Patent Analysis 11. Large Volume Wearable Injectors: Likely Drug Candidates 12. Emerging Trends on Social Media 13. Clinical Trial Analysis 14. Case Study: Role of CMOs in Device Development and Manufacturing 15. Regulatory and Reimbursement Landscape for Medical Devices 16. Market Sizing and Opportunity Analysis 17. SWOT Analysis 18. Executive Insights 19. Appendix 1: Tabulated Data 20. Appendix 2: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  6. According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability. Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19). The USD 1.1 billion (by 2030) financial opportunity within the Handheld Ultrasound Imaging Devices Market has been analyzed across the following segments: Application Area · Cardiac Scanning · Emergency Medicines · Gynecological / Obstetrics Scanning · Musculoskeletal Scanning · Pulmonary Scanning · Urological Scanning · Vascular Surgery · Other Application Areas Type of Transducer Array · Curved · Endocavity · Linear · Phased · Other Scanners Type of Software · Smartphone Applications · Customized Software End-Users · Ambulatory Surgical Centers · Diagnostic Imaging Centers · Hospitals · Maternity Clinics · Specialty Clinics · Other End-Users Key Geographical Regions · North America · Europe · Asia-Pacific and the Rest of the World For more information, please visit https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html The Global Handheld Ultrasound Imaging Devices Market, 2020-2030, report features the following companies, which we identified to be key players in this domain: · Aidmax Medical · Beijing Konted Medical Technology · Biim Ultrasound · BreastIT · Butterfly Network · CJ Medical · Clarius Mobile Health · EchoNous · Fujifilm · GE Healthcare · Guangzhou Top Medical Equipment · Healcerion · Interson Medical Instruments · Philips · Somax Systems · VINNO · WuHan Youkey Bio-Medical Electronics · Yor Labs Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Company Profiles 6. Brand Positioning Analysis of Key Players 7. Partnerships and Collaborations 8. Cost Saving Analysis 9. Demand Analysis 10. Market Forecast 11. End-User Specific Opportunity Analysis 12. Case Study: Impact of Coronavirus Outbreak 13. Conclusion 14. Executive Insights 15. Appendix 1: Tabulated Data 16. Appendix 2: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  7. Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Inclusions · A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology and others) and target disease indication(s), information on gene type, type of vector used, type of therapy (ex vivo and in vivo), mechanism of action, type of gene modification (gene augmentation, oncolytic viral therapy and others) and special drug designation (if any). · A discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vectors. · A world map representation, depicting the most active geographies, in terms of the presence of companies engaged in developing gene therapies, and a bull's eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy (ex vivo and in vivo). · A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies. · Detailed profiles of marketed and phase II/III and gene therapies, including a brief history of development, information on current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, along with information on the developer company. · An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development, namely prior to drug launch, at / during drug launch and post-marketing. · A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were / are being used for the development of four or more products / product candidates. · An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation. · An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019. The analysis also provides information on the key value drivers and deal multiples related to the mergers and acquisitions that we came across. · An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings. · An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio. · A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors. The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors. · A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain. · An analysis of the various factors that are likely to influence the pricing of gene-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies. For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Key therapeutic areas · Autoimmune disorders · Cardiovascular diseases · Genetic disorders · Hematological disorders · Metabolic disorders · Ophthalmic disorders · Oncological disorders · Others Type of vector · Adeno associated virus · Adenovirus · Herpes simplex virus type 1 · Lentivirus · Plasmid DNA · Retrovirus · Vaccinia Virus Type of therapy · Ex vivo · In vivo Type of gene modification · Gene augmentation · Immunotherapy · Oncolytic therapy · Others Route of administration · Intraarticular · Intracerebellar · Intramuscular · Intradermal · Intravenous · Intravitreal · Intravesical · Subretinal · Others Key geographical regions · North America · Europe · Asia-Pacific The report includes detailed transcripts of discussions held with the following experts: · Adam Rogers (CEO, Hemera Biosciences) · Al Hawkins (CEO, Milo Biotechnology) · Buel Dan Rodgers (Founder & CEO, AAVogen) · Cedric Szpirer (Executive & Scientific Director, Delphi Genetics) · Christopher Reinhard (CEO and Chairman, Cardium Therapeutics) · Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela) · Jeffrey Hung (CCO, Vigene Biosciences) · Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory) · Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics) · Robert Jan Lamers (CEO, Arthrogen) · Tom Wilton (Chief Business Officer, LogicBio Therapeutics) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  8. With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. The USD 6.9 billion financial opportunity (by 2030) within the Bispecific Antibody Therapeutics Market has been analyzed across the following segments: Therapeutic Area · Autoimmune Disorders · Eye Disorders · Genetic Disorders · Hematological Malignancies · Infectious Diseases · Inflammatory Disorders · Skin Disorders Mechanism of Action · Cytokines Retargeting / Neutralization · Dual Ligands Blocking · T-cell Retargeting / Activation · Others Target Antigens · CD3 x CD19 · CD30 x CD16A · Factor IXa x Factor X · IL-1α x IL-1β · IL-13 x IL-4 · IL-17A x Albumin · IL-17A x IL-17F · Psl x PcrV · VEGF-A x ANG2 · Others Antibody Formats · Asymmetric · Fragments · Symmetric · Others Key Geographical Regions · North America · Europe · Asia-Pacific For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain: · Amgen · Ablynx · AbbVie · Affibody · Affimed · Alphamab · AstraZeneca · Avillion · Chugai Pharmaceuticals · Eddingpharm · GSK · Merck · Merus · Roche · Regeneron Pharmaceuticals · Taisho Pharmaceuticals · Zymeworks Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Bispecific Antibody Therapeutics: Technology Platforms 6. Drug Profiles 7. Key Insights 8. Benchmark Analysis: Big Pharma Players 9. Partnerships and Collaborations 10. Contract Services for Bispecific Antibody Therapeutics 11. Clinical Trial Analysis 12. Case Study: Regulatory Guidelines for Bispecific Antibodies 13. Case Study: Promotional / Marketing Strategies 14. SWOT Analysis 15. Market Forecast and Opportunity Analysis 16. Concluding Remarks 17. Executive Insights 18. Appendix 1: Tabulated Data 19. Appendix 2: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
×
×
  • Create New...